Skip to main content

Table 1 Brief summary of 9 cases of intravascular large B-cell lymphoma

From: Frequency of intravascular large B-cell lymphoma in Japan: Study of the Osaka Lymphoma Study Group

Case

Age

Sex

Site

Treatment

Outcome (survival time)

1

60

f

lung

unknown

alive (111.8 months)

2

79

f

nasal cavity

THP-COP

dead

3

55

f

retroperitoneum

R-CHOP, auto PBSC, Radiation

alive (81.3 months)

4

62

f

lung

R-CHOP, auto PBSC, Radiation

alive (52 months)

5

69

f

lung

R-THP-COP

dead (30.6 months)

6

93

f

liver/spleen

Not done

Autopsy case

7

74

m

kidney

unknown

unknown

8

40

f

skin

R-CHOP

alive (20.0 months)

9

67

f

lung

unknown

alive (18.6 months)

  1. f:female, m: male
  2. THP-COP: pirarubicin, cyclophosphamide, vincristine and prednisolone
  3. R-CHOP: rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone
  4. R-THP-COP: rituximab-pirarubicin, cyclophosphamide, vincristine and prednisolone
  5. PBSC: peripheral blood stem cell transplantation